Zonisamide-induced weight loss in schizophrenia: Case series

Clinical Neuropharmacology

Volumn 33, Issue 2, 2010, Pages 104-106

  Yang, Jaewon ^a   Lee, Moon Soo ^a   Joe, Sook Haeng ^a   Jung, In Kwa ^a   Kim, Seung Hyun ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Obesity; Schizophrenia; Waist circumference; Weight loss; Zonisamide

Indexed keywords

AMISULPRIDE; BENZATROPINE; CLOZAPINE; DIAZEPAM; HALOPERIDOL; LORAZEPAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZONISAMIDE;

ADULT; ANAMNESIS; ARTICLE; BODY MASS; BODY WEIGHT; CASE REPORT; DRUG DOSE INCREASE; ELECTROCONVULSIVE THERAPY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MALE; PARANOID SCHIZOPHRENIA; PARESTHESIA; PRIORITY JOURNAL; REFRACTORY SCHIZOPHRENIA; SCHIZOPHRENIA; SIDE EFFECT; UNDIFFERENTIATED SCHIZOPHRENIA; VITAL SIGN; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; SCHIZOPHRENIA; WEIGHT GAIN; WEIGHT LOSS;

EID: 77951071549     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181c848a0     Document Type: Article

References (17)

1. The American Diabetes Association, the American Psychiatric Association, the American Association of Clinical Endocrinologists, and The North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-272.
2. McIntyre RS, Mancini DA, Basile VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001;62:23-29.
3. Faught E, Ayala R, Montouris GG, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57:1774-1779.
4. Oommen KJ, Mathews S. Zonisamide: a new antiepileptic drug. Clin Neuropharmacol 1999;22:192-200.
5. Gadde KM, Franciscy DM, Wagner HR 2nd, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289:1820-1825.
6. Okada M, Hirano T, Kawata Y, et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res 1999;34:187-197.
7. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995;22:193-205.
8. Anand A, Bukhari L, Jennings SA, et al. A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. J Clin Psychiatry 2005;66:195-198.
9. Tosches WA, Tisdell J. Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. Epilepsy Behav 2006;8:522-526.
10. McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 2006;67:1897-1906.
11. McElroy SL, Kotwal R, Hudson JI, et al. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry 2004;65:50-56.
12. McElroy SL, Suppes T, Keck PE Jr, et al. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. J Clin Psychiatry 2005;66:617-624.
13. Wang PW, Yang YS, Chandler RA, et al. Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study. J Psychiatr Res 2008;42:451-457.
14. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005;65:1391-1418.
15. Ichikawa J, Chung YC, Dai J, et al. Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release. Brain Res 2005;1052:56-62.
16. Terry P, Gilbert DB, Cooper SJ. Dopamine receptor subtype agonists and feeding behavior. Obes Res 1995;3(suppl 4): 515S-523S.
17. Wallingford NM, Sinnayah P, Bymaster FP, et al. Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology 2008;33:2922-2933.